Edwards Lifesciences 2005 Annual Report"
For five years, Godefroy B., a 38 year-old father
of two, had been experiencing increasing fatigue, irritability
and impatience, but never considered the possibility that his symptoms
could be related to a heart condition. It was only after he suffered
two fainting incidents, including one while pulling his young son on
a sled one wintry morning, that doctors diagnosed a congenitally malformed
and severely calcified aortic heart valve that required immediate replacement.
After consulting with his surgeon, Godefroy chose to receive the Carpentier-Edwards Magna pericardial heart valve. “The heart valve procedure changed my life,” he says. “I am now a better person, father and husband. Thank you for giving me back everything that I was on the verge of losing.”
Designed specifically to optimize patient blood flow and facilitate placement
above the patient’s native valve
opening, Edwards’ PERIMOUNT Magna aortic valve is
the leading heart valve in the U.S. and the first and only
therapy of its kind to combine more than two decades of clinical
experience and innovation with Edwards’ advanced tissue treatment
technologies.